Literature DB >> 2295112

Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.

B Sundman-Engberg1, U Tidefelt, J Liliemark, C Paul.   

Abstract

A comparison of intracellular concentrations of daunorubicin, doxorubicin and ara-C in myeloid blast cells was carried out in vivo and in vitro. In vivo, blood samples were obtained from 27 patients with acute nonlymphoblastic leukemia during and up to 4 days after drug infusion. Leukemic cells were isolated and drug concentrations were determined by HPLC. Before treatment, leukemic cells from 21 patients were isolated from blood and bone marrow, and in vitro incubations were done with anthracyclines for 1-3 h at concentrations of 0.1-1.0 microM and with ara-C for 1 h to 5 days at concentrations of 0.5-5.0 microM. The cells were cultured for 5 days, during which cell samples were taken for drug determination. The results showed that incubation with 0.2 microM daunorubicin for 1 h and 0.2 microM doxorubicin for 3 h and continuous exposure to 0.5 microM ara-C gave intracellular concentration curves similar to those obtained in vivo. After 5 days' culture, the cytotoxic effect was determined by vital dye staining with fast green, the addition of an internal standard of fixed goose erythrocytes, cytospin centrifugation and counter-staining of living cells with haematoxylin/eosin (DiSC). Incubations at the above-mentioned concentrations exerted a cytotoxic effect of approximately 50%. We conclude that in mimicking the in vivo situation, it is important to consider differences in intracellular pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295112     DOI: 10.1007/bf00684881

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.

Authors:  L M Weisenthal; P L Dill; J Z Finklestein; T E Duarte; J A Baker; E M Moran
Journal:  Cancer Treat Rep       Date:  1986-11

2.  Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.

Authors:  C Paul; J Liliemark; U Tidefelt; G Gahrton; C Peterson
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

3.  Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts.

Authors:  G Noel; C Peterson; A Trouet; P Tulkens
Journal:  Eur J Cancer       Date:  1978-04       Impact factor: 9.162

4.  Use of in vitro tests in predictive cancer chemotherapy.

Authors:  A W Hamburger
Journal:  J Natl Cancer Inst       Date:  1981-06       Impact factor: 13.506

5.  Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.

Authors:  J O Liliemark; W Plunkett; D O Dixon
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

6.  Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.

Authors:  C Paul; C Peterson; G Gahrton; D Lockner
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Clinical correlations of drug sensitivity in the human tumor stem cell assay.

Authors:  S E Salmon; D S Alberts; B G Durie; F L Meyskens; S E Jones; B Soehnlen; H S Chen; T Moon
Journal:  Recent Results Cancer Res       Date:  1980

8.  A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.

Authors:  L M Weisenthal; J A Marsden; P L Dill; C K Macaluso
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

9.  Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells.

Authors:  R Baurain; A Zenebergh; A Trouet
Journal:  J Chromatogr       Date:  1978-09-21

10.  High remission-induction rate in acute myeloid leukaemia.

Authors:  R P Gale; M J Cline
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

View more
  3 in total

1.  Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Authors:  A Andersen; D J Warren; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.

Authors:  Katie F Maass; Chethana Kulkarni; Mohiuddin A Quadir; Paula T Hammond; Alison M Betts; Karl Dane Wittrup
Journal:  J Pharm Sci       Date:  2015-09-07       Impact factor: 3.534

3.  Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Authors:  U Tidefelt; B Sundman-Engberg; C Paul
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.